@FiercePharma: Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. Story | Follow @FiercePharma
@TracyStaton: From FiercePharmaMarketing: UCB nabs Asian marketing rights to hot Biogen MS drugs. More | Follow @TracyStaton
@EricPFierce: My colleague Mark Hollmer offers a thoughtful analysis of pacemakers after having one put in. Check it out. Item | Follow @EricPFierce
@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce
> PDL Biopharma said it had settled its royalty disputes with Roche ($RHHBY), in a deal that grants it royalties on sales of the cancer drugs Avastin, Herceptin, Kadcyla, and Perjeta, as well as the asthma drug Xolair and eye drug Lucentis. Report
> A Swiss proposal to restrict immigration would interfere with drugmakers' ability to recruit skilled workers, Roche ($RHHBY) CEO Severin Schwan said, noting that half of the company's R&D staff are not Swiss, and nor is he. Report
> A U.S. appeals court affirmed a failure-to-warn verdict against Novartis ($NVS), even though the doctor who prescribed its drugs Zometa and Aredia said he didn't read the drug warnings. Report
> The Swedish drugmaker Recipharm tapped two local banks to advise on a potential stock market listing this year. Report
> Vertex Pharmaceuticals ($VRTX) cut the ribbon on its new Boston headquarters, which will house all of its area workers, including 1,200 already in place and another 100 moving in this quarter. Report
> Endo Health Solutions ($ENDP) wrapped up its sale of its HealthTronics unit to Altaris Capital for up to $130 million in cash and milestones. Report
@FierceMedDev: FDA: Kids with diabetes can use DexCom's continuous glucose monitor. Story | Follow @FierceMedDev
@MarkHFierce: Here's my perspective, as a patient, on the pacemaker industry. Editor's corner | Follow @MarkHFierce
@MichaelGFierce: Lupin stakes a claim on the sterile injectables market. News | Follow @MichaelGFierce
@EmilyWFierce: Endo waves goodbye to HealthTronics for $130M. Report | Follow @EmilyWFierce
> Boston Scientific appears to turn a corner as sales growth gains momentum. More
> Thermo Fisher closes $13.6B Life Tech acquisition. Item
Biotech News
@FierceBiotech: Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success. More | Follow @FierceBiotech
@JohnCFierce: Furiex preps for buyout talks after IBS drug looks promising in PhIII. News | Follow @JohnCFierce
@DamianFierce: Big Pharma superteam joins NIH to share data, discover new drugs. Story | Follow @DamianFierce
@EmilyMFierce: Mechanism that boosts bone growth could aid osteoporosis drug design. Article via FierceBiotech Research | Follow @EmilyMFierce
> NEA backs $14M round for a biotech startup focused on autism disorder. More
> Acucela spots a $162M Japanese IPO to get its eye drug into focus. Read
Biotech Research News
> $40M gift from stem cell agency will fund new genomics initiative. Item
> Exposure to acid turns adult cells into stem cells. More
> Merck halts drug testing on chimpanzees. News
> Mechanism that boosts bone growth could aid osteoporosis drug design. Report
> Stem cell signaling protein spurs cancer spread. Story
> Epilepsy drug reverses fatty liver disease in obese mice. Article
Pharma Manufacturing News
> Daiichi Sankyo is bringing the hammer down on Ranbaxy. More
> Amgen is halting Epogen manufacturing in Colorado. Story
> Abbott is closing a plant in Puerto Rico as Mexico's Neolpharma expands. Article
> Alexion buys vial-filling facility in Ireland. News
> Lupin stakes a claim on the sterile injectables market. Report
> Sources: Recipharm looks at doing an IPO to expand cash. Item
And Finally... A sugary diet can double the risk of heart disease, a new study found. Report